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Highlights 
 Leber hereditary optic neuropathy (LHON) is a mitochondrial optic neuropathy 
(MON) 
 Primary open angle glaucoma (POAG) can be a MON 
 LHON and POAG risk factors include reduced mitochondrial DNA (mtDNA) quantity 
 Increasing mtDNA levels is a potential MON therapeutic option  
 
Leber hereditary optic neuropathy (LHON) is a rare, inherited mitochondrial disease. No treatment has shown a clear-
cut benefit on a clinically meaningful end-point. Primary open-angle glaucoma is a frequent, acquired optic 
neuropathy. Lowering intraocular pressure reduces disease progression. However, current methods to decelerate this 
progression are recognized as being inadequate. Therefore, there is a clear need to look for new therapeutic 
approaches. The growing evidence indicates that primary open-angle glaucoma can also be a mitochondrial optic 
neuropathy (MON). Several risk elements are common for both diseases and all of them decrease mitochondrial 
(mt)DNA content. Based on these susceptibility factors and their molecular mechanism, we suggest herein 
pharmacological therapies targeted to increase mtDNA levels, oxidative phosphorylation capability, and mitochondrial 
energy production as treatments for MONs. 
 
Keywords: LHON; POAG; RGCs; mitochondrial biogenesis; mtDNA; pharmacological therapy. 
Teaser: Drugs that increase mitochondrial biogenesis are potential therapies for the mitochondrial optic neuropathies 
LHON and POAG. 
 
Introduction 
Optic neuropathies are an important cause of blindness worldwide. In many cases, a primary or secondary 
mitochondrial dysfunction, affecting retinal ganglion cell (RGC) survival, is the cause of these optic neuropathies. 
Unfortunately, there are no approved treatments for MONs. However, given the common risk factors for primary 
and secondary MONs, we propose herein pharmaceutical drugs that improve oxidative phosphorylation (OXPHOS) 
function and provide RGC protection in animal models. 
Energy source in retinal ganglion cells 
Retinal photoreceptor cells capture light information and, via bipolar and amacrine cells, conduct it to RGC 
dendrites and then down the optic nerve formed by RGC axons to the brain. Of the integrated sensory signals in 
the brain, 90% are of visual origin, which gives an indication of the work load of RGCs. RGC axons traverse the 
lamina cribrosa and their myelination is post laminar. The saltatory conduction in myelinated axons is more 
efficient, because depolarization and repolarization only occur at the nodes of Ranvier. By contrast, unmyelinated 
prelaminar and laminar RGC axons do not perform saltatory conduction and require a higher density of voltage-
gated sodium channels and sodium/potassium ATP pumps. Therefore, the propagation of action potentials in these 
segments of the optic nerve demands greater energy consumption. Thus, these higher ATP demands explain why 
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 physiologically increased numbers of mitochondria are found in RGC unmyelinated axons and why these cells are 
so vulnerable to OXPHOS impairments [1]. 
OXPHOS is a mitochondrial biochemical pathway that is more efficient than cytosolic glycolysis for ATP 
production, and is the main energy source for neurons. This system includes the electron transport chain (ETC) and 
ATP synthases. The ETC contains the respiratory complexes I (CI) to IV (CIV,), in which the reduction of NADH to 
oxygen electrons transfer is accompanied by protons pumped from the mitochondrial matrix to the intermembrane 
space, thus generating a proton electrochemical gradient. ATP is then synthesized when these protons come back to 
the matrix via ATP synthase. The first ETC complex, NADH:ubiquinone oxidoreductase, or CI, takes electrons 
from NADH produced after nutrient oxidation and transports them to the ETC. CI includes 44 different 
polypeptides, 37 encoded by genes on nuclear chromosomes and seven (p.MT-ND1-6 and p.MT-ND4L) by genes in 
mtDNA. These seven subunits are involved in proton pumping. Therefore, mutations in these proteins can affect 
OXPHOS function [2], which can then affect RGC survival; loss of RGCs can lead to blindness. 
Inherited and acquired mitochondrial optic neuropathies 
Leber hereditary optic neuropathy 
LHON is a type of blindness that results from RGC dysfunction and loss. It is characterized by severe acute or 
subacute central vision loss in one eye followed soon thereafter by the other eye, and associated with dense central 
or centrocecal scotomas and impaired color vision. Pathological cupping of the optic disc is also a feature of 
longstanding LHON. The peak age of onset is during the second and third decades of life and its reported 
prevalence is <0.003 % [3]. CI specific activity and CI-driven ATP production rates are reduced in LHON 
lymphoblasts [4]. This disorder results mainly from pathologic mutations in mtDNA genes encoding CI subunits. 
Three of these mutations [m.3460G>A (MT-ND1), m.11778G>A (MT-ND4), and m.14484T>C (MT-ND6)] account 
for most cases of LHON, with a plethora of rare mutations accounting for the remaining cases [3]. However, most of 
these mutations are not severe and many carriers fail to express the phenotype [5]. Therefore, other factors must 
be involved in addition to the pathologic mutation. In fact, different mtDNA genetic backgrounds, such as 
haplogroup J, defined by particular combinations of genetic variants in this molecule, increase the risk for the 
disease [6]. It has been also found that males are especially affected and more than two-thirds of unaffected 
homoplasmic carriers are female [7]. Smoking increases LHON penetrance [8] and it has also been suggested that 
antiretroviral therapy triggers visual loss in individuals harboring LHON mutations [9]. Unfortunately, there are 
currently no Phase 1 clinical trial data supporting the use of any medication for the treatment of LHON [10]. 
Primary open-angle glaucoma 
Primary open-angle glaucoma (POAG) represents approximately 85% of all glaucoma cases. Its global prevalence is 
3.1 % for people aged 40 years or older. It is characterized by visual field defects, cupping of the optic disc, normal-
appearing anterior chamber angle, and raised intraocular pressure (IOP). POAG is also the most-frequent cause of 
irreversible blindness and, similar to LHON, results from loss of RGC [11]. POAG is a multifactorial disorder [12], 
and likely represents a common phenotype resulting from several underlying pathophysiologies [4]. There is 
mounting evidence that, in some cases, POAG is a MON [4]. Similar to LHON, mitochondrial respiratory activity is 
decreased in POAG lymphoblasts [13]. These cells also exhibited lower CI specific activity, CI-driven respiration, 
and CI-driven ATP production rates. However, these CI functional defects in POAG were milder than in LHON 
[4,14]. It was also reported that, in glaucoma-resistant individuals, with raised IOP over many years and no optic 
neuropathy, lymphocyte ATP generation by ETC complexes was higher than that of control or susceptible 
individuals, with fast-progressing glaucoma and low IOP [15]. Although LHON mutations have been reported in 
patients with POAG [16,17], these or other mtDNA pathologic mutations are not a major cause of POAG. However, 
somatic mutations accumulate in mtDNA with increasing age [18], and age is an important risk factor for the 
disease, with POAG prevalence increasing with age [19]. Another significant risk factor for POAG is a raised IOP. 
Unilateral IOP elevation can be induced by episcleral vein cauterization (EVC) to establish a model of glaucoma, 
and an increased number of RGC mtDNA mutations and lower mtDNA levels were found in EVC eyes than in 
contralateral eyes. These changes were accompanied by significant reductions in CI activity [20]. Thus, all these 
results support mitochondrial dysfunction as another risk factor for some patients with POAG. 
A bias of POAG maternal inheritance, compatible with mtDNA maternal inheritance, has also been reported 
[21–25]. Moreover, the number of mtDNA segregating sites, especially those in coding regions and also those 
nonsynonymous in CI genes, was higher in patients with POAG than in controls [26]. Similar to LHON, mtDNA 
haplogroups are also risk factors for glaucoma [27,28]. A higher POAG prevalence has been also reported in men 
than in women [19,29]. There also appears to be a potential association between POAG and heavy smoking [30]. 
Finally, a significant increase in the frequency of glaucoma was observed in patients treated with antiretroviral 
therapy [31]. 
Given that LHON and POAG share several risk factors, here we provide a deep analysis of these factors that 
could provide clues to potential therapies. 
New therapies for mitochondrial optic neuropathy  
It has been observed that estradiol, the levels of which are higher in females, increases mtDNA content, oxygen 
consumption, and ATP levels in human cybrids harboring LHON mutations, which could explain the lower 
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 prevalence of LHON in females [32]. By contrast, it was found that a significantly increased POAG risk was 
associated with later and earlier age of menarche and menopause, respectively, and the use of oral contraceptives 
for more than 5 years. Pregnancy is associated with decreased IOP during the third trimester. Therefore, increased 
estrogen states could confer neuroprotective effects and reduce POAG risk [33]. In fact, estradiol also increases 
mtDNA content, oxygen consumption, and ATP levels in human cybrids with no LHON mutations [32]. 
Interestingly, some studies report differences in peripheral blood mtDNA content between men and women [34] 
and, although it is not easy to carry out epidemiological studies on mtDNA copy number in human tissues distinct 
than blood, it was found that mtDNA levels in nontumorous liver tissue from male patients with hepatocellular 
carcinoma was significantly lower than that of female patients [35]. 
Other LHON and POAG risk factors, whether genetics, such as mtDNA haplogroup, or environmental, such as 
smoking or antiretroviral therapy, have also been associated with smaller amounts of mtDNA [36–38]. Thus, 
mtDNA levels were lower in haplogroup J than in H cybrids [36]. Smoking was significantly associated with the 
lowest blood mtDNA content in affected individuals. Moreover, cigarette smoke also condensate decreased 
fibroblast mtDNA copy number [37]. mtDNA depletion was observed in offspring from mothers with HIV-1 given 
zidovudine therapy [38]. These facts could explain why healthy LHON mutation carriers show higher blood mtDNA 
levels than do patients [7], and why glaucoma-resistant individuals also have a higher lymphocyte mtDNA content 
[15]. Although the quantity of RGC mtDNA from patients with MON is not known, the previous observations 
suggest a therapeutic strategy for MON that involves increasing mitochondrial biogenesis and, thus, mtDNA 
levels. 
Mitochondrial biogenesis 
We performed a PubMed bibliographic review (May 2017) using ‘mitochondrial biogenesis’ and ‘mtDNA’ as search 
terms and selected compounds that increase mtDNA copy number. Although environmental chemicals, such as 
benzene, hydrogen sulfide, methylmercury, perfluorooctanoate, or sulfur dioxide, increase mtDNA content, 
toxicities associated with them hamper their use as therapeutic agents. Other molecules associated with higher 
mtDNA levels are not so toxic (Table 1). A set of these drugs has been repeatedly associated with an increased 
mtDNA amount. For example, lipoic acid, lipoamide, thiazolidinediones, or polyphenols increase mtDNA copy 
number in varied cell types or tissues from mice, rats, and humans. This increase in mtDNA levels is frequently 
accompanied by elevation of mtDNA-encoded RNAs and proteins, number and activity of OXPHOS complexes, 
oxygen consumption, and amount of ATP. 
Protective effects of retinal ganglion cells 
Rotenone is a CI inhibitor that has been used to generate animal models of LHON [39]. Thus, following a daily 
intraperitoneal rotenone administration for 10 days, an increase in RGC apoptosis was observed. However, 
rosiglitazone treatment for 10 days after the administration of rotenone, significantly reduced the number of 
apoptotic RGCs [40]. Experimental induction of elevated IOP is frequently used to generate animal models of 
POAG [41]. It was reported that resveratrol significantly delayed RGC loss in a glaucoma model induced by 
injecting hyaluronic acid into the rat anterior chamber [42]. Given that RGC damage is a characteristic of both 
LHON and POAG, we conducted a literature search for animal models of RGC degeneration in which the 
compounds discussed above were tested. We performed a PubMed bibliographic review (May 2017) using the search 
terms ‘retinal ganglion cells’ and ‘the particular drug’ and selected for those compounds with an RGC 
neuroprotective effect shown in animal models. Many of the previously cited compounds had already been shown to 
have beneficial effects of RGC in different animal models (Table 2). 
Prevention and treatment of mitochondrial optic neuropathies 
Significant changes in retinal structure occur during the conversion to LHON. Although a loss of RGC is 
documented in LHON, significant spontaneous recovery of visual acuity has been reported in 5–65% of cases, 
depending on the pathologic mutation [5]. This recovery commonly occurs during the first year, but is usually 
incomplete. Interestingly, significant vision recovery can occur without apparent retinal structure recovery [43]. 
During the earlier stages of glaucoma, RGCs have the capacity to recover function following periods of functional 
loss [44]. The mechanism for vision recovery is not understood but might be linked to the mitochondria of the RGCs 
that remain. Therefore, some of the compounds discussed above could be LHON therapies. By contrast, the 
administration of some of these drugs before the generation of RGC lesions could prevent posterior damage. For 
example, pretreatment with lipoic acid or ω-3 polyunsaturated fatty acids decreased RGC apoptosis in animal 
models (Table 2) [XX]. 
There are several scenarios in which these potential therapies might be important for MON. For example, they 
might be preventive treatments. POAG is not a common disease before 40 years of age. Thus, young maternal 
relatives of patients with POAG would be candidates for such therapy. Healthy carriers of LHON mutations would 
also be candidates. The peak incidence of LHON occurs during in the mid-20s [45]. Thus, younger individuals 
carrying the mutations are at risk and could benefit from these drugs. Moreover, in 75% of patients with LHON, 
the second eye is affected 2 or 3 months after the first. However, an interval greater than 12 months [46], even up 
to 18 years [47], occurs in some cases. In general, POAG is a bilateral disease, although the course of disease 
progression is often asymmetric, with one eye more adversely affected than the other eye [48]. Therefore, the 
sequential bilateral nature of MON can provide a window of opportunity for preventive treatment. Finally, some 
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 patients with LHON spontaneously recover. It might be that supplying RGCs with these compounds could increase 
the chance of recovery. As previously discussed, different combinations of factors can result in POAG. Therefore, 
those POAG cases involving OXPHOS dysfunction would benefit from these therapies. The different therapeutic 
approaches to MON, including the drugs mentioned here, are reviewed elsewhere. [49]. 
 
Concluding remarks 
Some of the drugs discussed above have shown beneficial effects in mouse models of a variety of pathologies, 
including diabetes, liver steatosis,; acute kidney injury;, Parkinson’s disease, and X-linked adrenoleukodystrophy 
(see the supplemental references in the supplementary information online). Moreover, some of these compounds are 
already used in humans. Thus, increasing the amount of mtDNA and mitochondrial biogenesis should be now 
considered a potential therapeutic strategy for a range of diseases, including MON. 
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 Table 1. Compounds that increase mitochondrial DNA copy numbera,b 
Compound Cell/tissue Animal 
Acetyl-L-carnitine Brain, liver, muscle Rat 
All-trans retinoic acid Hepatocytes, HepG2 cell line Human 
Liver, 3T3-L1 cell line Mouse 
Benzene Blood  Human 
Caffeine Myotubes Rat 
Catalpol Muscle  Mouse 
cGMP-PDEase inhibitors (cilostamide, 
trequinsin, sildenafil) 
Kidney Mouse 
Conjugated linoleic acid Myotubes Mouse 
DL-3-n-butylphthalide H9c2 cell line Rat 
Fatty acids Muscle Rat 
Forskolin Adipocytes Human 
Hydrogen sulfide Hepatocytes, smooth muscle cells Mouse 
Idebenone Early neural progenitor cells Human 
Lipoamide, Lipoic acid  Adipocytes, ARPE-19 cell line Human 
3T3-L1 cell line Mouse 
Liver Rat 
Lithium chloride Dami cell line  Human 
Methylmercury Immortalized neural progenitor cells Human 
Nicotinamide riboside Fibroblasts Human 
Muscle Mouse 
Perfluorooctanoate Liver Rat 
Polyphenols (curcumin, 
epigallocatechin gallate, hydroxytyrosol, 
oligonol, quercetin, resveratrol, rutin) 
Coronary arterial endothelial cells, fibroblasts, HepG2 cell line, muscle, umbilical vein endothelial 
cells 
Human 
Aorta, brain, brown adipose tissue, kidney, liver, MN9D cell line, muscle, 3T3-L1 cell line Mouse 
Brain, hepatocytes, kidney, muscle, PC12 cell line Rat 
PPARα agonist (pirinixic acid) Adipocytes Human 
Pyrroloquinoline quinone Early neural progenitor cells Human; 
Hepa1-6 cell line Mouse 
S-nitrosoacetyl penicillamine Brown adipoctyes Mouse 
Sphingosine 1-phosphate HepG2 cell line Human 
Sulfur dioxide Brain Rat 
Tetramethylpyrazine HeLa cell line Human 
Thiazolidinediones (ciglitazone, 
pioglitazone, rosiglitazone) 
Adipose tissue, NT2 cell line, SH-SY5Y cell line, umbilical vein endothelial cells Human 
Adipose tissue, brain, C2C12 cell line, spinal cord, 3T3-L1 cell line Mouse 
Thyroxine Liver Rat 
Valproic acid Fibroblasts Human 
β-adrenoceptor agonists (formoterol, 
nebivolol, carvedilol) 
Umbilical vein endothelial cells Human 
Heart, kidney, 3T3-L1 cell line Mouse 
Renal proximal tubule cells Rabbit 
Δ9-tetrahydrocannabinol SH-SY5Y cell line Human 
ω-3 PUFAs (DHA, EPA) Brown adipocytes, C2C12 cell line, white adipocytes  Mouse 
AICAR HeLa cell line, umbilical vein endothelial cells  Human 
5-HT 1F receptor agonist (LY344864) Heart, kidney, liver Mouse 
aAbbreviations: AICAR, 5-aminoimidazole-4-carboxamide ribonucleoside; cGMP-PDEase inhibitors, cyclic guanosine monophosphate-selective phosphodiesterase 
inhibitors; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; PPARα, peroxisome proliferator-activated receptor alpha; ω-3 PUFAs, omega-3 
polyunsaturated fatty acids; 5-HT, 5-hydroxytryptamine. 
bGrey background indicates toxic compounds. Bibliographic references for all these compounds can be found in the supplementary 
information online 
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 Table 2. Compounds with retinal ganglion cell neuroprotective effectsa 
Compounds Model Animal 
All-trans retinoic acid ON axotomy Frog 
Caffeine IOP (VC) Rat 
Forskolin IOP (anterior chamber saline infusion) Rat 
Idebenone Rotenone (intravitreal injection) Mouse 
Lipoic acid ONC Cat 
Diabetes, IOP (DBA/2J) Mouse 
IOP (anterior chamber methylcellulose injection), ONC Rat 
Lithium chloride ONC Rat 
Nicotinamide riboside EAE Mouse 
Polyphenols (epigallocatechin gallate, resveratrol) EAE, IOP (anterior chamber microbeads injection), ONC Mouse 
IOP (intracameral hyaluronic acid injection) Rat 
Sphingosine 1-phosphate analog (fingolimod) IOP (microbeads injection) Rat 
Tetramethylpyrazine Intravitreal NMDA injection Rat 
Thiazolidinediones (pioglitazone, rosiglitazone) ONC, Rotenone (intraperitoneal injection) Rat 
Valproic acid NTG (GLAST KO) Mouse 
ONC Rat 
Δ9-tetrahydrocannabinol IOP (VC) Rat 
ω-3 PUFAs (DHA, EPA) ONC Mouse 
IOP (VC), ONH lesion Rat 
aAbbreviations: DBA/2J, genetic model; DHA, docosahexaenoic acid; EAE, experimental autoimmune encephalomyelitis; EPA, eicosapentaenoic acid; GLAST KO, 
glutamato/aspartate transporter gene deletion genetic model; IOP, intraocular pressure; NMDA, N-methyl-D-Aspartate; NTG, normal tension glaucoma; ON, optic 
nerve; ONC, ON crush; ONH, optic nerve head; VC, veins cauterization; PUFAs, polyunsaturated fatty acids. 
Bibliographic references for all these compounds can be found in the Supplementary Material 
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